LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

Published 2018 View Full Article

Authors

Keywords

Journal

ANNALS OF ONCOLOGY

Volume 29, Issue suppl_9, Pages -

Publisher

Oxford University Press (OUP)

Online

2018-11-25

DOI

10.1093/annonc/mdy483

Ask authors/readers for more resources

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

ANNALS OF ONCOLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Become a Peeref-certified reviewer

Ask a Question. Answer a Question.